

BRAIN TUMORS (II): TOPOGRAPHICAL SYNDROMES, CLINICAL FEATURES, DIAGNOSIS AND TREATMENT



34484 Pathology of the nervous system

Neurosurgery

Topic 20

Prof. Vicente Vanaclocha

Prof. Pedro Roldan

Prof. Guillermo García-March

vivava@uv.es

pedro.roldan@uv.es

guillermo.garcia-march@uv.es



Key concepts

- **General aspects of brain tumours**
 - *Epidemiology*
 - *Clinical picture*
 - *Diagnosis*
 - *Neuroimaging*
 - *Tumour markers*
 - *General treatment*
- **Types (classification)**
- **Brain metastasis**
- **Meningeal carcinomatosis**
- **Gliomas**
- **Brain lymphoma**
- **Meningiomas**
- **Schwannomas**
- **Tumours of the glands (pituitary and pineal)**
- **Craniopharyngioma**
- **Medulloblastoma and ETMR**
- **Phacomatosis**



Simple teaching classification

REMEMBER?

1. **Metastases and meningeal carcinomatosis**
2. **Glia:** *astrocytoma, oligodendroglioma, primary lymphoma, ependymoma*
3. **Meninges:** *meningiomas*
4. **Nerve sheath:** *cranial nerve schwannomas, paraspinal*
5. **Neurons:** *ganglioglioma, neurocytoma*
6. **Glands:** *sellar region (hypophysis), pineal region*
7. **Choroid plexus:** *choroid plexus papilloma*
8. **Mesenchymal:** *glomus tumour, chordoma, solitary fibrous tumour (before hemangiopericytoma)*
9. **Embryonal remnants:** *craniopharyngioma, medulloblastoma, ETMR (embryonal tumour with multilayered rosettes, previously PNET)*



GLIAL TYPE TUMORS

REMEMBER?

- Cell types


Astrocytes → astrocytomas

Oligodendrocytes → oligodendrogliomas


Microglia → primary brain lymphoma

Ependymocytes → ependymomas


*Axial T1 C+
Astrocytoma*



*Axial T1 C+
Oligodendroglioma*



*Axial T1 C+
Primary lymphoma*




*Axial T1 C+
Ependymoma*



2. Oligodendroglioma

- Origin: oligodendroglia
- Epidemiology
 - Rare (4% tumours, 5-15% gliomas)
 - Male ~ 40 years
 - Supratentorial 90 % (frontal), not very aggressive (grades I-II)
- Symptoms
 - Epilepsy (initial and most frequent symptom) 90 %
 - Neurological deficit 30 %
 - Late symptoms (>7-8 years): headache and papilledema (raised intracranial pressure)





2. Oligodendroglioma

• Neuroimaging

- CT = hypodense SOL, cystic areas, calcifications (70 %)
- MRI = large SOL, delimited, without edema, low C+ uptake (low aggressiveness)
- MRI-spectroscopy = aggressive and mixed type cases


• Treatment

- Radical excision
- Radiotherapy / chemotherapy depending on aggressiveness



CT C+ (calcifications, low C+ uptake)

MRI axial T1 C+ (jelly cyst, delimited, low C+ uptake)




2. Oligodendroglioma

• Prognosis

- Codeletion 1p/19q → Better prognosis and response to chemotherapy (alkylating agents)
- Mixed tumours: oligoastrocytomas → prognosis = that of astrocytoma



histologically-defined anaplastic oligodendrogliomas




	Group 1: combined, isolated 1p + 19q loss	Group 2: 1p loss "other" *	Group 3: TP53 mutation	Group 4: no TP53 mutation**
age	43	51	30	52
response rate	(100%)	(100%)	(33%)	(18%)
duration response	>31 months	11 months	7 months	5 months
survival from dx	>123 months	71 months	71 months	16 months



3. Primary brain lymphoma



- Brain lymphoma (B cells)
 - **Primary** = Arises from microglia
 - Secondary to systemic lymphoma (more frequent than primary)







- Epidemiology
 - Rare (1% brain tumours)
 - Male ~ 40-50 years → 50-70 years
 - Immunocompromised (AIDS –EBV infection–, transplanted, elderly)
- Symptoms
 - Supratentorial SOL: cognitive alt, diplopia, dysphagia, vertigo...
 - Corticosteroids → Very marked but TRANSIENT response (“phantom tumour”)





3. Primary brain lymphoma

- Neuroimage
 - Dense lesion, single or multiple (40 %, especially AIDS), periventricular white matter
 - Perilesional edema, ring uptake C+ (depends on malignancy)
 - MRI-spectroscopy
- CSF: \uparrow proteins and \downarrow glucose
- Treatment
 - Confirm etiology \rightarrow Stereotactic biopsy
 - Protocols of hematology
 - Chemotherapy + radiotherapy



4. Ependymoma

- Origin: ependymal cells
 - Ventricles = young children < 20 years
→ fourth ventricle
 - Spinal canal = Adults → filum terminale
 - *Most frequent, most benign, best prognosis*
- Epidemiology
 - 5 % of gliomas (3% brain tumours)
- Symptoms
 - Raised intracranial pressure (12-18 months) - hydrocephalus: headache, vomiting, ataxia, vertigo
 - Invasion of brainstem
 - Seeding through CSF



4. Ependymoma





Metastasis
Neuroaxis


• Diagnosis

- Brain MRI
 - *Intraventricular tumour, homogeneous limits, content non-homogeneous*
 - *Obstructive hydrocephalus, with ↑ ventricular size depending on location of tumour*
- Spinal cord MRI (C+D+L)
- MRI-spectroscopy

RM T1 axial and sagittal



RM T2 coronal and sagittal



4. Ependymoma

• Pathology


- Grade I – subependymoma, mixopapillary ependymoma
- Grade II – ependymoma (papillary, clear cells...)
- Grade III – anaplastic ependymoma

• Treatment

- Surgery + radiotherapy ENTIRE NEUROAXIS + chemotherapy depending on aggressiveness.
 - *Radiotherapy children → psychomotor retardation (especiallly < 6 years)*
- Hydrocephalus → ventriculoperitoneal shunt / ventriculostomy

• Prognosis

- 5-year survival 80 %
- Recurrency 33 % in children
- Better prognosis if complete excision
- Worse if dissemination through neuroaxis



Simple teaching classification

REMEMBER?

1. **Metastases and meningeal carcinomatosis**
2. **Glia:** *astrocytoma, oligodendroglioma, primary lymphoma, ependymoma*
3. **Meninges:** *meningiomas*
4. **Nerve sheath:** *cranial nerve schwannomas, paraspinal*
5. **Neurons:** *ganglioglioma, neurocytoma*
6. **Glands:** *sellar region (hypophysis), pineal region*
7. **Choroid plexus:** *choroid plexus papilloma*
8. **Mesenchymal:** *glomus tumour, chordoma, solitary fibrous tumour (before hemangiopericytoma)*
9. **Embryonal remnants:** *craniopharyngioma, medulloblastoma, ETMR (embryonal tumour with multilayered rosettes, previously PNET)*



MENINGIOMAS

- Origin: arachnoid (arachnoid granulations)


- Epidemiology

- 2nd most common intracranial tumor (20 %)
 - *Most common extraparenchymal tumour*
- Female (2:1) age 40-60 years








- Characteristics

- Benign (95 %) → Most commonly found in autopsies
 - *Complete resection = healing*
- Slow expansive growth
 - *Encapsulated*
 - *Invades skull (not brain) and adjacent dura (dural tail)*
 - *Calcification (psammoma bodies)*





Meningiomas

- Location



Meningiomas

- Symptoms: depend on location
 - Compression adjacent structures
 - *Focal epilepsy, frontal syndrome (alterations behaviour)*
 - *Paresthesia or hypoesthesia*
 - *Hemianopsia*
 - *Cranial nerves involvement*
 - Lesser sphenoidal wing or olfactory groove → Foster-Kennedy syndrome (anosmia + homolateral optic atrophy + contralateral papilledema)
 - Foramen magnum → differential diagnosis with amyotrophic lateral sclerosis





Meningiomas

• Diagnosis

- Neuroimage → well-limited lesion, iso- or hyperintense
 - *Extra-axial tumour base in dura, homogeneous C+ uptake*
 - *Spectroscopy*
- Vascular study
 - *Diagnostic or therapeutic angiography (vascular supply from internal carotid – meningeal artery)*
 - *Embolization*
- Marker EMA (*epithelial membrane antigen*)

*Simple Rx:
giant frontal
meningioma*








*Falcian meningioma – MRI and
angiography of vascular supply*

Meningiomas


• Treatment

- Expectant: observation
 - *Lineal progressive growth 4.94 cc/year ($\approx \uparrow \varnothing 0.37$ cm/year)*
 - *23 % do not grow*
 - *Patients in poor physical status, elderly, $\varnothing < 1$ cm and asymptomatic, refusal to undergo surgery*
- Complete resection = tumour + infiltrated dura and bone
 - *Survival > 90 % at 5 years*
 - *Recurrence 11-15 % at 5 years*
- Partial resection or atypical (malignant)
 - *Fractional radiotherapy*
 - *Radiosurgery (if remainder < 3 cm)*
 - *Recurrence 37-85 % at 5 years*








SCHWANNOMAS (neurinoma)

- Origin: Schwann cells of nerve roots
 - Any nerve root or cranial nerve EXCEPT the second (with oligodendroglia, not Schwann cells!)
 - Most common in eighth > fifth > seventh
 - “Acoustic neurinoma”, but it is vestibular branch
- Most common CPA tumour
 - Differential diagnosis: cranial base meningioma, epidermoid
- Epidemiology
 - 8 % intracranial tumours
 - Benign slow growth
 - Female, middle-aged (> 30 years)
 - When bilateral (< 40 years) = diagnostic criterion NF-II



Schwannomas


- Symptoms (eighth > fifth > seventh)
 - Tinnitus (98 %)
 - Neurosensorial hearing loss (70 %)
 - Balance disturbance (67 %)
 - Headache, facial paresthesia (30 %)
 - Facial paresis, diplopia (10 %)




Schwannomas

- Diagnosis: MRI (*isodense CT*)
 - T1 isointense, but T1 C+ good uptake
 - T2 sequences
- Screening NF-II
 - Autosomal dominant
 - Loss of function of NF2 tumour suppressor gene in 22q12.2.



(2°) Trigeminal



(3°) Facial



(4°) Jugular foramen
(IX, X, XI)




(1°) Vestibular



Vestibular bilateral


Schwannomas





- Treatment = “surgery, and if it is not possible, radiotherapy”. BUT:
 - Tumour $\varnothing < 2\text{cm}$ asymptomatic and age > 70 years \rightarrow control growth (RM)
 - Tumour $\varnothing 2\text{-}3\text{ cm}$ or bilateral \rightarrow radiosurgery
 - Tumour $\varnothing > 3\text{ cm}$ \rightarrow surgical resection
 - *Tumour remnants* \rightarrow radiosurgery





- Malignant schwannoma:
 - MPNST = *malignant peripheral nerve sheath tumour* (peripheral nerve neurofibrosarcomas)
 - Associated with NF-I (Von Recklinghausen)
 - Consider chemotherapy (Bevacizumab in study)



NEURONAL TUMORS



- Gangliocytomas and gangliogliomas
 - Mixed neuronal + glial cells
 - *Glial determine aggressiveness*
 - Rare (1 %), children-young adults
 - Location
 - *Temporal → Resistant epilepsy*
 - *Cerebellum: Lhermitte-Duclos Disease*
 - Diagnosis: MRI
 - *Looks like low grade astrocytoma, but no edema + no C+ uptake*
 - Treatment = surgery
 - *+ radiotherapy if remnants or malignant*



Simple teaching classification



REMEMBER?

1. **Metastases and meningeal carcinomatosis**
2. **Glia:** *astrocytoma, oligodendroglioma, primary lymphoma, ependymoma*
3. **Meninges:** *meningiomas*
4. **Nerve sheath:** *cranial nerves schwannomas, paraspinal*
5. **Neurons:** *ganglioglioma, neurocytoma*
6. **Glands:** *sellar region (hypophysis), pineal region*
7. **Choroid plexus:** *choroid plexus papilloma*
8. **Mesenchymal:** *glomus tumour, chordoma, solitary fibrous tumour (before hemangiopericytoma)*
9. **Embryonal remnants:** *craniopharyngioma, medulloblastoma, ETMR (embryonal tumour with multilayered rosettes, previously PNET)*



SELLAR REGION TUMOURS


- Adenohypophysis (>>> neurohypophysis)
 - Benign (>>> malignant, 0.5%)
 - Involve the sella turcica
 - *NOT meningioma & craniopharyngioma*
- Incidence
 - 10 % primary brain tumours
 - Women 20-40 years old
 - Incidental finding in 25 % cases
 - MEN-I (*multiple endocrine neoplasia type I*)
 - *Parathyroid gland, pancreas and pituitary adenomas (40-50 years)*
 - *Autosomal dominant 11q13*



SELLAR REGION TUMORS


• According to secretion

- Secreting or functioning (> 70 %)
 - *PRL > GH*
 - *Mixed PRL-GH*
 - *ACTH*
 - *Other hormones*
- Non-secreting (chromophobes)



• According to size

- Microadenoma (< 1 cm)
- Macroadenoma (> 1-2 cm)



Microadenoma





Macroadenoma





SELLAR REGION TUMOURS

- Endocrine symptoms
 - Endocrine hyperfunction
 - Amenorrhea-galactorrhea (♂ sexual impotence), infertility
 - Gigantism (children) / acromegaly (adults)
 - Cushing's syndrome caused by \uparrow ACTH (= Cushing's disease)
 - Thyrotoxicosis
 - Pituitary insufficiency (compression)
 - FSH-LH \rightarrow TSH \rightarrow remainder
 - Hypopituitarism
 - Children: dwarfism
 - Pituitary apoplexy (rare)





SELLAR REGION TUMOURS

- Symptoms due to mass effect
 - Visual loss due to chiasm compression
 - *Bitemporal hemianopia*
 - Other symptoms
 - *Cavernous sinus* → *third, fourth, fifth, and sixth cranial nerves*
 - *Rhinoliquorrhea (rare)*





SELLAR REGION TUMOURS

- Diagnosis + response to treatment
 - Endocrine evaluation
 - *Hormonal involvement*
 - *Response to treatment, relapses*
 - Campimetry
 - Neuroimaging
 - *CT sella turcica → enlargement, erosion, peritumoral calcification*
 - **Brain and pituitary MRI** → *boundaries and extent, necrosis, haemorrhage*
 - *Microadenoma: angiography → petrosal sinus catheterization*





SELLAR REGION TUMOURS

- Indication for surgical treatment
 - Pituitary apoplexy → URGENT
 - Macroadenoma with progressive mass effect
 - *Except prolactinoma: good response to medical treatment*
 - Hyperfunctioning
 - *Acromegaly, Cushing's, secondary hyperthyroidism*
 - Failure of hormonal medical treatment
 - Obtain histological diagnosis (non-functioning)




SELLAR REGION TUMORS

- Surgical treatment
 - Transnasal endoscopic route (transsphenoidal)
 - Craniotomy if large extrasellar invasion
- Radiotherapy - indications:
 - Giant tumours
 - Subtotal resection
 - *Radiosurgery?*



SELLAR REGION TUMORS

- Case 1: Prolactinoma
- Case 2: GH-secreting tumour
- Case 3: ACTH-secreting tumour
 - *Cushing's disease*
- Case 4: Non-functioning adenomas
- Case 5: Pituitary apoplexy



SELLAR REGION TUMOURS

• Case 1: Prolactinoma

– Medical treatment= Dopamine agonists
(Bromocriptine, cabergoline)

- *Reverses symptoms, but some do not respond*
- *Once started cannot stop*
- *Microprolactinoma → fertility 85 % cases*
- *Macroprolactinoma → adjuvant treatment to surgical removal*


– Pregnancy

- *Not teratogen*
- *↑ tumour \varnothing in 5-15 % cases*


– Surgical treatment if mass effect

- *Microadenomas → 88 % cure*
- *Macroadenoma → 28 % cure*

MRI T1 C+
BEFORE medical treatment



MRI T1 C+
3 months AFTER medical
treatment



SELLAR REGION TUMOURS

Somatuline® Depot (lanreotide) Injection

Preparation
Comes in ready-to-inject
premixed, prefilled syringes

Needle Length/Gauge
0.79 inches/19 gauge
(60 mg, 90 mg)
18 gauge (120 mg)

Injection Depth/Tissue
Deep subcutaneous
injection



Sandostatin® LAR Depot (octreotide acetate for injectable suspension)



Preparation
Requires multistep
mixing process

Needle Length/Gauge
1.5 inches to
2.0 inches/19 gauge

Injection Depth/Tissue
Intramuscular
injection




- Case 2: GH-secreting tumour
 - Medical treatment = somatostatin analogues (octreotid, lanreotid)
 - Antiproliferative effect, ↓GH, ↓tumour Ø
 - Dopamine analogues → Bromocriptine, cabergoline)
 - GH receptor antagonist → Pegvisomant
 - Surgical treatment
 - Microadenomas → curative treatment
 - Macroadenomas → maximum cytoreduction + medical treatment (relapses)
 - Radiotherapy
 - As an adjunct to surgery
 - Slows growth ~ 10 years
 - **RADIOSURGERY**



SELLAR REGION TUMOURS




- Case 3: ACTH secreting tumor
 - Cushing's syndrome features
 - Treatment = surgical
 - *Great improvement, 12 % relapses*
 - If surgical treatment fails:
 - *Radiotherapy ± radiosurgery*
 - *Palliative medical treatment*
 - Serotonin antagonists (↓ACTH synthesis)
 - Adrenal blockers
 - Glucagon antagonists
 - Last resort = bilateral adrenalectomy
 - *Nelson syndrome → corticotropic adenoma growth after adrenalectomy (skin hyperpigmentation)*



↑ACTH = Cushing's disease


SELLAR REGION TUMORS

- Case 4: Non-functioning adenomas
 - 25 % pituitary adenomas
 - Many are macroadenomas (35 %)
 - *Headache, visual disturbance, mild hyper-PRL, hypopituitarism, ↓libido*
 - Treatment = surgical
 - *Radiotherapy only if rapid progression*
 - Result: rarely recur





SELLAR REGION TUMOURS

- **Case 5: Pituitary apoplexy**
 - Haemorrhagic infarction in pituitary adenoma
 - Clinic: acute headache
 - *Meningismus, visual disturbance, ophthalmoplegia*
 - *Consciousness impairment*
 - *Hypopituitarism*
 - **Neurosurgical emergency**
 - *Vital to make diagnosis*
 - *Glucocorticoid replacement*
 - ***Urgent surgical decompression***




PINEAL REGION TUMOURS

- Most common in children-adolescents
- Clinical symptoms
 - Intracranial hypertension due to obstructive hydrocephalus → most frequent form of presentation (obstruction of the third ventricle / aqueduct Sylvius)
 - Oculomotor disorder due to midbrain involvement
 - *Parinaud's sign = upward gaze paralysis*
 - Neuroendocrine symptoms → Precocious puberty, hypothalamic dysfunction
 - Cerebellar disorders, spinal cord involvement (cerebrospinal fluid)



Pineal region tumors



- Diagnosis

- CSF tumour markers: not always present




- α fetoprotein → endodermal sinus tumour, embryonal carcinoma, teratoma
 - β hCG → choriocarcinoma, germinoma (10 %)
 - CEA (carcinoembryonic antigen)

- Neuroimaging

- Size-related malignancy, inhomogeneity, imprecise limits, high contrast uptake (highly vascularized)
 - Look for seeds (complete medullary MRI)

- BIOPSY


Biopsy
pineal
tumor



Pineal region tumours


- High histologic variation

- GERMINOMAS > astrocytomas, pineocytomas, pineoblastomas, non-germinomatous tumours (teratomas)



Pineal region tumours

Endoscopic
ventriculostomy




• Treatment


- Hydrocephalus → endoscopic Ventriculostomy (+ biopsy)
- Tumour = radio + chemotherapy (± surgery)
 - *If it is a germinoma, "it is sensitive to radio + chemotherapy" (other germ cells?)*
 - *Non-germ: surgery + radiotherapy + chemotherapy*
 - *Protocols variable according to hospital*

• Prognostic




- Average survival 5-6 years, but it is highly variable
- Better in germinal tumours (they respond to radiotherapy)



**Biopsy
pineal
tumor**



Pineal region tumours



• GERMINOMA

- Germinal cell tumours
- Adolescents (2nd decade)
- Third ventricle or pineal region
- Possible aggressive and invasive
- Clinical features:
 - Possible hypothalamic dysfunction (diabetes insipidus)
 - Visual field disturbance, hydrocephalus
- Sensitive to radio and chemotherapy
- 85% 5-year survival






Teaching classification

1. **Metastasis and meningeal carcinomatosis**
2. **Glia: astrocytoma, oligodendroglioma, primary lymphoma, ependymoma**
3. **Meninges: meningiomas**
4. **Nerve sheaths: cranial and paraspinal nerve schwannomas**
5. **Neurons: ganglioglioma, neurocytoma**
6. **Glands: sellar region (Pituitary tumours), pineal region**
7. **Choroid plexus: choroid plexus papilloma**
8. **Mesenchymal: glomus tumour, chordoma, solitary fibrous tumour (formerly hemangiopericytoma)**
9. **Embryonic remains: craniopharyngioma, medulloblastoma, ETMR (embryonal tumour with multilayered rosettes, formerly PNET)**







CHOROID PLEXUS TUMOUR

- Choroid plexus papilloma
 - Plexuses grow without invading parenchyma
 - Obstructive hydrocephalus
 - ↑ CSF production
 - Possibility of hemorrhages
 - Rarely malignant (carcinoma) but may have CSF seeding
- Incidence
 - 0.5 % intracranial tumours
 - Schoolchildren <12 years
- Location
 - Children → lateral ventricles – left side
 - Adults → fourth ventricles (50 %)
- Treatment = surgery
 - If anaplastic → + radiotherapy




MESENCHYMAL TUMOURS

- Glomus tumour
 - Glomus jugular tumour
 - Benign, well vascularized paraganglioma
 - Jugular foramen → IX-X-XI
 - Hearing loss, tinnitus, difficulty swallowing
 - Surgical treatment
- Chordoma
- Hemangiopericytoma






Mesenchymal tumours

- Glomus tumour
- Chordoma
 - Derived from notochord remnants
 - Clivus (25 %, ~ 35 years), sacrum (60 %, ~ 50 years) > other spinal areas
 - Aggressive, but slow growing
 - Age 50-60 years
 - Headache, fourth nerve involvement
 - Destruction clivus or parasellar region
 - Surgical treatment + radiotherapy / radiosurgery
 - Bad prognosis
- Hemangiopericytoma



Mesenchymal tumours

- Glomus tumour
- Chordoma
- Solitary fibrous tumour
 - Previously known as “hemangiopericytoma”
 - Age 45-55 years without gender predilection
 - Pathology = spindle cells
 - Grade I → Some grade II-III (= the ones previously known as hemangiopericytoma)
 - Similar to meningioma, rounder and firmer
 - Diagnosis = MRI
 - *Less intense signal on T2 than meningioma*
 - Treatment = surgical removal



EMBRYONARY REMNANT TUMOUR

- Tumours of dysembryoplastic origin

- **Craniopharyngioma**

- Colloid cyst third ventricle

- *Benign tumour with content PAS (+)*

- *Acute intermittent hydrocephalus due to Monro foramen blockage*

- Corpus callosum lipoma

- Dermoid and epidermoid tumours (cholesteatoma) → ENT

*PAS = PAS =
periodic acid Schiff*

- Tumours of embryonic remains (neural precursor cells)

- **Medulloblastoma** → Posterior fossa



- **ETMR** (*embryonal tumour with multilayered rosettes*, previously known as PNEembryonalT) → supratentorial

- Other tumours: neuroblastoma and estesioneuroblastoma





1. Craniopharyngioma

- Tumour of dysembryoplastic origin of the suprasellar region (2-4% brain tumours)
 - Origen = Rathke's pouch remnants and craniopharyngeal duct
 - Suprasellar 75 % > sellar and parasellar
- Features
 - Children and adolescents ♂
 - Grade I (seldom become malignant)
 - Calcifications and cystic component with oily content






Roof of the mouth:
Rathke's pouch



1. Craniopharyngioma

- Clinical picture
 - Neuroendocrine dysfunction
 - *Growth retardation, short stature, obesity*
 - Visual field impairment: chiasm compression from above
 - *Bitemporal hemianopia from the LOWER quadrants*
 - Raised intracranial pressure
 - *Cognitive disorder, hydrocephalus*
- Diagnosis = imaging
 - Cysts, calcifications, hydrocephalus
- Treatment = surgical removal
 - Adjuvant radiotherapy
 - \pm radiosurgery



2. Medulloblastoma

- The most common paediatric tumour



- 20-30 % childhood brain tumours
 - *“Most common tumour in young children (<6 years)”*
- Poorly differentiated, aggressive embryonal tumour
- Tendency to spread through CSF
- More frequent ♂
- Markers: 17p deletion
- Associated with Gorlin and Turcot syndromes (gliomapolyposis)

- Location

- Children (60 %) → Vermis cerebellum + roof fourth ventricle
- Adults 20 – 25 years → Cerebellar hemispheres

- Clinical picture

- Midline cerebellar syndrome (ataxia, dysmetria) + raised intracranial pressure




RM series T1 C+



2. Medulloblastoma

- Diagnosis = MRI
 - MRI CR → Tumour mass with homogeneous borders with hypodense areas (necrosis) and surrounding edema
 - MRI neuraxis (brain & spina cord)
 - Vascular study
 - CSF study (rule out CSF dissemination)
- Treatment
 - Excision as complete as possible
 - Radiotherapy fossa posterior + neuraxis
 - Chemotherapy systemic and intrathecal
- Survival
 - 50 % at 3 years
 - > 30 % at 5 years



3. Other embryonal tumours

- ETMR = *embryonal tumour with multilayered rosettes*
 - Previously known as PNET (*primitive neuroectodermal tumour*)
 - Similar to medulloblastoma, but supratentorial (suprasellar) and more aggressive (subarachnoid seeding in 35 %)
 - Treatment = surgery + brain and neuroaxis radiation therapy + chemotherapy
 - Survival 75% at 3 years
- Neuroblastoma
 - Adrenal tumour
 - “May appear as a primary CNS tumour”
- Esthesioneuroblastoma
 - It comes from olfactory mucosa embryonic cells



PHACOMATOSIS

- *Neurocutaneous syndromes*
 - *Autosomal dominant inheritance of variable penetrance*
- 1. Neurofibromatosis type 1
- 2. Neurofibromatosis type 2
- 3. Tuberous sclerosis (Pringle-Bourneville disease)
- 4. Sturge-Weber syndrome (encephalotrigeminal angiomatosis)
- 5. Von Hippel-Lindau syndrome
- 6. Klippel-Trenaunay syndrome
- 7. Ataxia-telangectasia (Louis-Barr syndrome)



Phacomatosis

1. Neurofibromatosis type I (NF-I) = Von Recklinghausen disease

– Skin lesions

- Peripheral nerve neurofibromas (benign, mollusca fibrosa)
- Skin pigmentation : +6 café au lait spots $\varnothing > 1,5 \text{ cm}$ = diagnosis of NF-I
- **Axillary ephelides** (freckles, Crowe's sign) = **PATHOGNOMONIC**
- Lisch nodules (iris pigmented hamartomas)

– Neurological injuries


– Others



COFFEE SPOT



- C** – café-au-lait spots
A – axillary/inguinal freckling
F – fibroma (neurofibroma +2, plexiform neurofibroma)
E – eye hamartoma (Lisch nodules)
S – skeletal abnormalities
P – positive family history
OT – optic nerve glioma



Phacomatosis

1. Neurofibromatosis type I (NF-I) = Von Recklinghausen disease



– Skin lesions

– Neurological injuries

- *NF1 chromosome 17 gene mutation (17q11.2, encodes neurofibromin, tumour suppressor)*
- *Risk of nervous system neoplasms → plexiform neurofibromas, optic nerve glioma, pheochromocytoma, ependymoma, meningiomas, astrocytomas*
- *Neurofibromas of nerve trunks → do not exist at birth. Image in hourglass*

– Others:



- *Pseudoarthrosis of the tibia, sphenoid wing dysplasia, kyphoscoliosis, short stature, aqueduct of Silvio stenosis (hydrocephalus), mental retardation (45%), epilepsy, renal artery stenosis, “2nd arterial hypertension to pheochromocytoma”, ...*



Phacomatosis

2. “Neurofibromatosis” type II (NF-II)

- Skin lesions= seldom
 - Neurological lesions
 - **NF2** gene mutation, chromosome **22** (22q12, encodes neurofibromin-2, merlin or schwannomas, tumour suppressor)
 - **Bilateral** eighth nerve schwannoma (90% of carriers of the gene) → unilateral onset deafness at **20-30** years of age
 - Meningiomas, gliomas, and schwannomas (cranial and spinal nerves)
- **MISME** = **m**ultiple **i**ntracranial (**i**nherited) **s**chwannomas, **m**eningiomas, **e**pendymomas syndrome (**NOT NEUROFIBROMAS**)
- Others
 - Syringohydromyelia, cataracts



Phacomatosis

3. Tuberosus sclerosis = Pringle-Bourneville disease

- **EPI-LOI-A** (**epilepsy, low intelligence, angiofibromas**) 30 % patients
 - *Vogt's triad = ASI = angiofibromas, seizures, intellectual disability*
 - *TSC1 (hamartin at 9q32-34) and TSC2 (tuberin at 16p13.3) genes*
- Skin lesions
 - *Sebaceous adenomas (facial angiofibromas) = yellowish-pink "butterfly" papules on cheeks (age 3-10 years)*
 - *Hypopigmented spots on ash leaf (age 0-1 years)*
 - *Chagrin patches = lumbosacral skin thickening*
 - *Periungual fibromas (Koenen tumours) = **PATHOGNOMONIC***
- Neurological lesions
- Others



Ash leaf lesion




Koenen tumour

Phacomatosis

3. Tuberosous sclerosis = Pringle-Bourneville disease

- Skin lesions
- Neurological lesions → epilepsy (West syndrome), mental retardation, hydrocephalus
 - *Cortical tubers*
 - *Subependymal astrocytoma of giant cells*
 - *Multiple calcified periventricular nodules*
 - *Multiple retinal astrocytomas*
- Others: Neoplasms
 - *Cardiac rhabdomyomas*
 - *Renal, hepatic, adrenal, pancreatic angiomyomas*
 - *Ependymomas, astrocytomas (“90% subependymal giant cell astrocytomas”)*
 - *“Cystic lung disease (honeycomb lung)”*



Primary diagnostic criteria (+
angiofibromas and ungual
fibromas)



Roberto Sánchez
(Román in the film
“Campeones”)

Phacomatosis

4. Sturge-Weber syndrome (encephalotrigeminal angiomatosis)

– Sporadic

- *Embryonic development defect: persistence of vascular plexus in the cephalic portion of the neural tube*

– V1 facial angioma + ipsilateral occipital leptomeningeal angioma and choroidal angioma


– Skin lesions

- *Port wine stain (V1 distribution, one-sided)*

– Neurological lesions

- *Leptomeningeal, venous, occipitoparietal angiomatosis*
- *Epilepsy, intellectual impairment*
- *Motor deficit (contralateral hemiplegia), homonymous hemianopia (occipital lobe lesion)*

– Others




MRI axial T1 C+ fatsat





Phacomatosis

4. Sturge-Weber syndrome (encephalotrigeminal angiomatosis)

- V1 facial angioma + ipsilateral occipital leptomeningeal angioma and choroidal angioma
- Skin lesions
- Neurological lesions
- Others
 - *Choroidal angioma, glaucoma blindness*
 - *Double contour subcortical calcification (“tram-track sign”)*



MRI T1 C+ (occipital lesion - contralateral homonymous hemianopia)




Phacomatosis

5. Von Hippel-Lindau syndrome



- Retina malformation and cerebellum alteration. Uncommon skin lesions (5 %)
 - *Tumour suppressor gene mutation VHL (3p25.5)*
- Clinical features
 - *Retinal angiomas*
 - *Cerebellar hemangioblastoma*
 - ↳ *“Erythropoietin → polycythaemia”*
- Others
 - *Spinal cord haemangioma*
 - *Hypernephroma, renal cell carcinoma*
 - *Pheochromocytoma*
 - *Kidney, liver, pancreatic, epididymal cysts*

H – Hemangioblastoma
I – Increased risk renal cell cancer
P – Pheochromocytoma
P – Pancreatic lesions (cysts, cystadenoma, cystadenocarcinoma)
E – Eye (retinal) hemangioblastoma, Endolymphatic sac tumours
L – Liver, renal, pancreatic, epididimal cysts



Phacomatosis

6. Klippel-Trenaunay syndrome (1:100.000)
 - Capillary + venous + lymphatic malformation
 - + *Arteriovenous fistula* = *Parkes-Weber syndrome*
 - Trunk and limb hemangiomas
 - Hypertrophy of the affected limb (macromelia, localized gigantism)
 - Spinal cord vascular malformation





Phacomatosis

7. Ataxia-Telangiectasia (Louis-Barr syndrome)

- Mutation 11q22-23
- Affects skin, nervous system, immune
- Clinical features

- *Children* → progressive cerebellar ataxia, oculomotor apraxia, choreoathetosis
 - Vermis atrophy and ↑fourth ventricle, possible bleeding
- *Oculocutaneous telangiectasias* (conjunctiva, ear, face)
- *Immunodeficiency* → Thymus hypoplasia (↓ T cells in blood and lymphoid tissue)
 - B cells normal, possible ↓IgG
 - Absence IgE and IgA
 - Sinusitis, respiratory infections (bronchiectasis), lymphoreticular tumours
 - ↑ αFP y CEAe

Not to be confused with hereditary hemorrhagic telangiectasia (Rendu Osler-Weber syndrome)

Telangiectasia


Neurodegeneration

Immunodeficiency

Tumours

Sterility

Radio sensibility



Finally, some associations:

DISEASE	CNS NEOPLASIA
NF-I (Von Recklinghausen disease)	Optic nerve glioma
NF-II	Bilateral neuroma VIII
Sclerosis tuberosa (Pringle Bourneville syndrome)	Subependymal giant cell astrocytomas
Sturge-Weber syndrome (encephalotrigeminal angiomatosis)	Cerebral angiomas
Von Hippel-Lindau syndrome	Cerebellar hemangioblastoma
Klippel-Trenaunay syndrome	Spinal cord cavernous angioma
MEN-I	Pituitary hyperplasia or adenoma
Turcot syndrome	Astrocytomas, medulloblastoma
HIV infection	Primary brain lymphoma



SUMMARY KEY CONCEPTS TOPIC 6

- **Oligodendroglioma**
 - ♂, *not very aggressive, hardly distinguishable, the most epileptogenic*
 - 1p19q deletion = good response to chemotherapy
- **Primary brain lymphoma**
 - ♂ immunosuppressed
 - Treatment by the haematology department. Surgery and corticosteroids NOT recommended
- **Ependymoma**
 - Child-young ventricles and invades brainstem, filum terminale in adults
 - Possible spread by CSF. Bad prognosis
- **Meningioma**
 - 2nd most frequent intracranial tumour, benign
 - ♀ middle age, calcifications. Surgery (+ radiotherapy and / chemotherapy if remnants)



- Schwannoma
 - VIII bilateral → NF-II diagnosis. Treatment according to size
- Pituitary tumours → hormonal disturbance + vision loss
- Pineal region tumours → histological variety (biopsy needed)
 - Germinomas respond to radiotherapy
- Choroid plexus papilloma
 - Children lateral ventricles, fourth ventricle in adults
- Craniopharyngioma
 - Children and adolescents ♂, dysembryoplastic tumour, benign
 - Calcifications, cystic, suprasellar. Surgery + radiotherapy
- Medulloblastoma
 - Most common paediatric tumour, poor prognosis



- Some typical features

- Epileptogenic → oligodendroglioma
- Calcifications → craniopharyngioma, oligodendroglioma, meningioma (psammoma bodies)
- Bleeding
 - *Primary* → glioblastoma multiforme, medulloblastoma, oligodendroglioma, pituitary adenoma
 - *Metastases* → choriocarcinoma, melanoma, lung, kidney, thyroid
- Distribution by gender
 - *Meningioma, neurinoma schwannoma* - Female ♀
 - *Glioma, medulloblastoma* - Male ♂



Bibliography (1)

- <https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments>
- <https://www.mayoclinic.org/es-es/diseases-conditions>. Página en castellano
- <https://radiopaedia.org/cases>
- Izquierdo Rojo JM, Martín Lázaro R, Puntó Rafael JI. Neurocirugía básica para residentes. Acceso pdf en la Biblioteca Nacional (www.bne.es > solicitar reproducción de fondos)
- Greenberg M.S. Handbook of Neurosurgery. Thieme. 7ª ed. 2010. Inglés.
- Greenberg M.S. Manual de Neurocirugía. Ed Journal, 2013. 2ª ed de la 7ª ed en inglés (ejemplares disponibles en la biblioteca).
- Greenberg M.S. Handbook of Neurosurgery. Thieme. 9ª ed. 2018. Inglés
- Agarwal V. Fundamentals Neurosurgery. Thieme 1ª ed. 2018 Inglés
- Bartomeus Jene, F. Nociones básicas de Neurocirugía. Pub. Permanyer. Lab Esteve. 2ª ed. 2011.

Free specialised bibliography (2)

- <https://braintumor.org/wp-content/assets/WHO-Central-Nervous-System-Tumor-Classification.pdf>
- Radiopaedia.org
- Oligodendroglioma: pathology, molecular mechanisms and markers. Wesseling P, van den Bent M, Perry A. *Acta Neuropathol* 2015;129(6):809-827
- Primary CNS lymphoma in HIV infection. Brandsma D, Bromberg JEC. *Handb Clin Neurol* 2018;153:177-186
- Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. Marinoff AE, Ma C, Guo D et al. *J Neurooncol* 2017 Oct;135(1):201-211
- Meningioma. Alruwaili AS, De Jesus O. En: StatPearls <https://www.ncbi.nlm.nih.gov/books/NBK560538/>
- Pituitary tumors. Melmed S. *Endocrinol Metab Clin North Am* 2015 Mar;44(1):1-9
- Third ventricular tumors: A comprehensive Literature Review. Ahmed SI, Javed G, Laghari AA et al. *Cureus* 2018 Oct;10(10):e3417
- Craneopharyngioma. Garnett MR, Puget S, Grill J et al. *Orphanet J Rare Dis.* 2007; 2: 18.
- Medulloblastoma. Mahapatra S, Amsbaugh MJ. En: StatPearls (internet) <https://www.ncbi.nlm.nih.gov/books/NBK431069/>



vivava@uv.es

pedro.roldan@uv.es

guillermo.garcia-march@uv.es